The Supply Chain Behind Radiopharmaceuticals: What Investors Need to Know
The logistics infrastructure behind radiopharmaceuticals is one of the most demanding — and least understood — supply chains in healthcare. As investment activity accelerates in nuclear medicine and radioligand therapy, understanding what it actually takes to move these products is increasingly relevant to diligence and thesis development.
Why Radiopharmaceutical Logistics Is Uniquely Complex
Unlike conventional pharmaceuticals, radiopharmaceuticals carry a dual regulatory burden — simultaneously classified as Dangerous Goods governed by IAEA transport regulations, and as pharmaceutical products subject to GDP compliance requirements. A qualified logistics operator must satisfy both frameworks: certified for Class 7 dangerous goods handling, employing trained personnel, and maintaining full traceability at every step. And unlike conventional pharmaceuticals — where temperature control and transit time are managed constraints — radiopharmaceuticals offer no such flexibility. Once manufactured, decay begins immediately and irreversibly. The supply chain must perform on the first attempt, every time.
That time pressure takes two distinct forms depending on the therapy type. Diagnostic radiopharmaceuticals move on tight same-day schedules from radiopharmacy to hospital or imaging center — specialists like Life Couriers, AirNet, and SDS Rx (now part of DHL) have built entire business models around networks designed around decay curves rather than shipper convenience. Therapeutic radiopharmaceuticals — including the radioligand therapies reaching commercial scale for prostate and neuroendocrine cancers — are a different challenge entirely. Many are patient-specific: a dose manufactured for a named patient, at a named facility, on a named treatment day. A failed delivery is not a supply chain inconvenience — it is a cancelled cancer treatment. World Courier (Cencora), Marken and MNX (UPS Healthcare), and PHSE have each built the specialist capability to operate at this level — and the pattern of global carriers acquiring this expertise is itself a signal about where the defensible value in this segment lies.
The Regulatory Barrier Is the Moat
Operating in radiopharmaceutical logistics requires regulatory authorization, infrastructure, and trained personnel that standard logistics operators cannot quickly replicate. Carriers need specific federal permits, NRC facility licenses, and dedicated infrastructure — radiopharmaceuticals cannot flow through standard sort facilities or warehouse receiving docks. Even within UPS's own network, MNX-handled radiopharmaceuticals are tendered directly planeside, bypassing the small package sort entirely. The workforce is equally specialized — dedicated, vetted employees trained in radiation safety protocols, not a contractor pool that can be scaled overnight. These requirements are earned through years of operational history and regulatory compliance — they cannot be shortcut. Which is precisely why, when UPS and DHL wanted to compete in this market, they acquired operators who had already built them: UPS acquired MNX, DHL acquired SDS Rx. The infrastructure requirement is not a compliance formality — it is a structural separation that defines who can and cannot operate in this market.
The Market Opportunity
The global nuclear medicine market was valued at approximately $17.8 billion in 2024 and is projected to reach $34.5 billion by 2030, growing at a compound annual growth rate of approximately 10%.¹ The therapeutic segment — radioligand therapy and targeted cancer treatment — is the fastest-growing component, advancing at nearly 20% annually and expected to more than triple in size by 2030.² The critical inflection point is commercialization: as these therapies move from clinical trials to commercial distribution, the logistics infrastructure supporting them must deliver the same level of precision at dramatically greater volume — more patients, more treatment cycles, more markets, more regulatory environments. That transition from clinical to commercial scale is where the logistics challenge becomes a logistics opportunity.
The Investment Implications
The complexity of radiopharmaceutical logistics creates meaningful barriers to entry — but those barriers are not simply about capital. They are about regulatory authorization, trained personnel, validated processes, and operational track record built over years, not quarters.
For investors, this creates two distinct implications. First, established specialist operators carry genuine competitive advantages that are difficult to replicate quickly — their moat is regulatory standing, workforce expertise, and trusted relationships with manufacturers and hospital systems, not infrastructure that can simply be purchased. Second, as radioligand therapy and other targeted treatments move from clinical to commercial scale, demand for qualified logistics capacity will grow faster than new supply can be credibly built. That structural imbalance — growing therapy volumes, constrained specialist capacity — is worth understanding before evaluating any asset in this segment.
The Scale Question
The counterweight to specialist advantage is the scale demand that commercialization creates. As radioligand therapies, biologics, and next-generation radiopharmaceuticals move from clinical trial populations to global commercial distribution, the logistics networks supporting them must scale across more countries, more regulatory jurisdictions, and more distribution points than any specialist operator currently serves alone.
UPS Healthcare has built its response through acquisition — Marken, MNX — combined with purpose-built GDP-certified infrastructure. DHL Life Sciences has committed €2 billion through 2030, adding CryoPDP and SDS Rx to its expanding pharma hub network. FedEx Life Sciences has pursued an organic path to date, building dedicated life science centers across Europe and Asia-Pacific. Two signals, however, suggest inorganic moves may follow: FedEx has publicly committed to concentrating resources on high-value precision verticals, and its new standalone Life Sciences organization — reporting nearly $10 billion in healthcare revenue — signals deliberate strategic focus rather than opportunistic business. If the UPS and DHL playbooks are any guide, dedicated healthcare divisions at global carriers tend to precede acquisitions. For investors tracking M&A activity in specialty healthcare logistics, FedEx Life Sciences is worth watching.
The competitive question is not whether specialist or generalist wins — it is which combination of expertise and network reach best serves each therapy class at each stage of commercialization.
The Bottom Line
Radiopharmaceutical logistics is not a niche that scale alone can conquer. It rewards deep operational expertise, regulatory rigor, and established relationships with manufacturers and hospital systems. For investors evaluating assets in this space — whether logistics operators, pharmaceutical manufacturers, or enabling technology providers — understanding the supply chain is inseparable from understanding the investment.
Sources
¹ Grand View Research, Nuclear Medicine Market Size, Share & Trends Analysis Report, 2025. grandviewresearch.com
² Mordor Intelligence, Nuclear Medicine Market — Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025–2030), June 2025. mordorintelligence.com
Jim Poole is the founder of JP Strategies LLC, a deal advisory firm serving private equity and executive search firms in healthcare logistics, parcel, and last-mile markets. He previously served as Healthcare Strategy Director at UPS.
